{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Brazil Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/br/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/br/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Brazil, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:f0a7380096de4910a9affacdf3f89f3158618d1b0511c0aeef0500b94f109bec", "url": "https://finance.yahoo.com/healthcare/articles/lqda-q2-earnings-top-strong-174700731.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lqda-q2-earnings-top-strong-174700731.html", "title": "LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth", "content_text": "Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues surged to $171.7 million from $8.8 million in the year-ago quarter and beat the Zacks Consensus Estimate of $165 million. The quarterly performance was powered by continued adoption of lead drug Yutrepia. However, shares were down 10% following the second-quarter results. Shares of LQDA have surged 128.5% year to date compared with the industry's growth of 5.", "date_published": "2026-08-13T17:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:356b9804c9a950cf8dc50d3ef8ffae3b5a2bb261fcdebe7b7d66a4ec0cf11c6d", "url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "title": "Zoetis (ZTS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on a reported basis and a 1% decline on an organic operational basis driven by a 1% decrease in volume.Adjusted Net Income -- $781 million, declining 2% on an organic operational basis.Adjusted Diluted EPS -- $1.87, representing 4% growth year over year and benefiting from a lower share count.U.S. Segment Revenue ", "date_published": "2026-08-13T12:01:05+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:ee14ce42f2260efb1bb1db5ed6d1a90068117e17a2c2d82448063d1c37ab25ef", "url": "https://finance.yahoo.com/markets/stocks/articles/beta-technologies-inc-beta-q2-230243612.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/beta-technologies-inc-beta-q2-230243612.html", "title": "BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenue in Q2 2026 was $14.7 million, exceeding guidance and up 146% year-over-year, driven by EPFD program and charger deliveries. Backlog reached 1,001 aircraft valued at $3.9 billion, nearly hitting the $4 billion year-end target by mid-year. Achieved significant certification milestones, including resolving FAA policy issues for the H500A motor and completing the CX-300 requirements definition phase. Lau", "date_published": "2026-08-12T23:02:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:92ffa359c02c60ed49053463f5130434b67e8043638b44555e31d17fc52f8956", "url": "https://finance.yahoo.com/m/9076b597-fa9d-353b-b767-fcf0c94c5835/why-no.-2-ibd-50-stock%2C.html", "external_url": "https://finance.yahoo.com/m/9076b597-fa9d-353b-b767-fcf0c94c5835/why-no.-2-ibd-50-stock%2C.html", "title": "Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat", "content_text": "Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. Continue Reading", "date_published": "2026-08-12T15:40:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:2c6ce9b6b9180d28e3a6cba7632ef1d84608a139e70ffd49856b59f3cf7b7ff4", "url": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tse-4502-wins-231825907.html", "external_url": "https://finance.yahoo.com/healthcare/articles/takeda-pharmaceutical-tse-4502-wins-231825907.html", "title": "Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment guidance and reaffirmed its fiscal 2027 earnings outlook. See our latest analysis for Takeda Pharmaceutical. The ORZEYFUL approval and refreshed guidance arrive as Takeda Pharmaceutical trades at \u00a55,582, with a 7 day share price return of 5.6% and a year to date share price return of 13.6%. Over a longer hor", "date_published": "2026-08-11T23:18:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "TAKP34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TAKP34", "name": "Takeda Pharmaceutical Company Limited", "sentiment_url": "https://sharemaestro.com/sentiment/8cd97599-ad6b-4ba9-9cdd-c5a3b9e0ab13/"}]}}, {"id": "source:3500a57047360e70f35836c633f932504b42bc1fe74342cc971537dbaf0821a5", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNaDI3czM1aFpUMzVzejJqZWM0VUw1QnpINTFzN0pJY1pXZHZTRTFieTFJOUhpVmZhWENwbDdfMk1EUzNLbG10YW00TUJYVTlVVlliblhHZm83V2hVZlRrNUhYMEE2MDdTUDNKY1QxcE1BazN4Q0FEZXdpV0NXUHVzRlB5UHpaWmhFcmt5bHB4eFlGT3V4ZFB0SXZKSHJYOVFTS2toUDVIYkI1SHhMbGZyNnNSR3FWLXVLakFwMw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNaDI3czM1aFpUMzVzejJqZWM0VUw1QnpINTFzN0pJY1pXZHZTRTFieTFJOUhpVmZhWENwbDdfMk1EUzNLbG10YW00TUJYVTlVVlliblhHZm83V2hVZlRrNUhYMEE2MDdTUDNKY1QxcE1BazN4Q0FEZXdpV0NXUHVzRlB5UHpaWmhFcmt5bHB4eFlGT3V4ZFB0SXZKSHJYOVFTS2toUDVIYkI1SHhMbGZyNnNSR3FWLXVLakFwMw?oc=5", "title": "CEO da United Therapeutics vende US$ 5,05 milh\u00f5es em a\u00e7\u00f5es - Investing.com Brasil", "content_text": "CEO da United Therapeutics vende US$ 5,05 milh\u00f5es em a\u00e7\u00f5es - Investing.com Brasil", "date_published": "2026-08-11T12:02:00+00:00", "authors": [{"name": "Finan\u00e7as, C\u00e2mbio e Investimentos"}], "tags": ["Market update", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:3140ec8cc640c38ca24b29fc29c971c9deac3e750d58aafa7b3fa671440f283c", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-zts-looked-winner-went-130909398.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-zts-looked-winner-went-130909398.html", "title": "Zoetis (ZTS) Looked Like a Winner. What Went Wrong?", "content_text": "Brown Advisory, an investment management company, released its \"Brown Advisory Global Leaders Strategy\" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second quarter of 2026, underperforming its benchmark, the MSCI ACWI Net Index, which returned 14.9%. The relative weakness was driven mainly by underexposure to semiconductors and technology hardware, while software, cloud services, and financial holdings also weighed on performance. The strategy benefited from holdings in areas tied to AI infrastructure, with semiconductor exposure and AI-related investments gaining from strong demand. Looking ahead, Brown Advisory sees an attractive environment for active stock-picking, with its ready-to-buy list at its highest level since the COVID-19 period and an estimated 12%-13% average five-year base-case IRR, while maintaining a focus on quality, valuation discipline, and long-term cash-flow generation. In addition, please check the Fund's top five holdings to know its best picks in 2026. In its second-quarter 2026 investor letter, Brown Advisory Global Leaders Strategy Fund highlighted stocks like Zoetis Inc. (NYSE:ZTS). Zoetis Inc. (NYSE:ZTS) is a global animal health company developing medicines, vaccines, and diagnostic products for livestock and companion animals. The one-month return of Zoetis Inc. (NYSE:ZTS) was -3.62% while its shares traded between $71.47 and $160.48 over the last 52 weeks. On August 7, 2026, Zoetis Inc. (NYSE:ZTS) stock closed at approximately $77.27 per share, with a market capitalization of about $30.02 billion. Brown Advisory Global Leaders Strategy Fund stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2026 investor letter: We exited Zoetis Inc. (NYSE:ZTS) in May. We were attracted to the investment due to its position as the largest pure-play animal health company, benefiting from significant scale in R&D and as the highest-quality marketer to veterinarians and livestock producers, which increases switching costs. The company had further shifted its business mix meaningfully toward a higher and more profitable contribution from its companion animal segment. Our investment in Zoetis began to face increased growth headwinds in 2025 due to incremental competition in its industry-leading dermatology and Simparica Trio products. Additionally, the launch of Librela\u2014the first available therapy for osteoarthritis pain in dogs\u2014underperformed our expectations. Furthermore, we have observed increased competition across Zoetis's main franchises and, most recently, Zoetis also saw generic competition in therapeutic categories. Several concerns have emerged: (1) despite the high barriers to entry in animal health, competition in the sector has intensified during our ownership; (2) we do not have enough visibility on their pipeline to assess the path of future contribution at this point; and (3) we misinterpreted Zoetis's ability to contribute to the portfolio from a deferrable demand perspective, as it did not deliver the defensiveness we expected. As such, we see our investment thesis in Zoetis as broken and have fully exited the position. Story Continues Zoetis (ZTS) Looked Like a Winner. What Went Wrong? Photo by Karlo Tottoc on Unsplash Zoetis Inc. (NYSE:ZTS) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 57 hedge fund portfolios held Zoetis Inc. (NYSE:ZTS) at the end of the first quarter, which was 69 in the previous quarter. While we acknowledge the risk and potential of Zoetis Inc. (NYSE:ZTS) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on", "date_published": "2026-08-10T13:09:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:24cf8de2843a954e370cf6a7d57f34f669f7f9201bea3765cf7e76566e9f534e", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE55YkRvVmFnT2pERmZVaUNwVDdQTHZXbzR4cC0zRnJ2OE5uU0VPN3lTVVZoWFVHUm9Hb0M5bmRqaTN2UFpVeW9YMy1MVkJzeUc1dXNBX1dsV2FwTWtMdjZUX2M0cmNEMTViVmc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTE55YkRvVmFnT2pERmZVaUNwVDdQTHZXbzR4cC0zRnJ2OE5uU0VPN3lTVVZoWFVHUm9Hb0M5bmRqaTN2UFpVeW9YMy1MVkJzeUc1dXNBX1dsV2FwTWtMdjZUX2M0cmNEMTViVmc?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: United Therapeutics Corp (UTHR) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: United Therapeutics Corp (UTHR) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-10T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:a5b082ee21530caa0ec5a13ac1d1081707b0bf2bdc113f3cdb9cce2541e4d6d6", "url": "https://finance.yahoo.com/markets/stocks/articles/zts-q2-deep-dive-leadership-032522195.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zts-q2-deep-dive-leadership-032522195.html", "title": "ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance", "content_text": "ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts' estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts' consensus estimates. Is now the time to buy ZTS? Find out in our full research report (it's free). Zoetis (ZTS) Q2 CY2026 Highlights: Revenue: $2.47 billion vs analyst estimates of $2.50 billion (flat year on year, 1.5% miss) Adjusted EPS: $1.87 vs analyst estimates of $1.85 (1% beat) The company dropped its revenue guidance for the full year to $9.22 billion at the midpoint from $9.82 billion, a 6.1% decrease Management lowered its full-year Adjusted EPS guidance to $6.20 at the midpoint, a 10.5% decrease Operating Margin: 37.4%, down from 39.1% in the same quarter last year Market Capitalization: $32.39 billion StockStory's Take Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market's positive reaction was underpinned by management's acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, \"Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have outpaced broader consumer inflation.\" The company highlighted resilience in its Livestock and Diagnostics segments, despite softness within dermatology and parasiticides. Looking forward, Zoetis lowered its full-year revenue and profit guidance, citing continued competition and value-conscious behavior from pet owners. Management plans to sharpen commercial execution, enhance cost discipline, and accelerate innovation, especially within its dermatology and diagnostics portfolios. Peck explained, \"We are responding with focus and discipline, sharpening execution in Companion Animal, allocating capital with discipline, exercising greater cost discipline, and continuing to advance the innovation that has always differentiated Zoetis.\" The company's revised outlook reflects expectations that current headwinds in the U.S. Companion Animal market will persist into the second half of the year. Key Insights from Management's Remarks Management attributed Q2 performance to sustained U.S. clinic traffic declines, increased promotional activity in core categories, and shifts in leadership designed to improve execution and agility. Story Continues U.S. Companion Animal Weakness: The company saw continued declines in U.S. veterinary clinic visits, particularly affecting premium therapies in dermatology and parasiticides. Management highlighted that \"pet owners have become more selective in how they spend,\" leading to pressure in key franchises like Apoquel and Simparica Trio. Elevated Competition and Promotions: Zoetis reported intensified competition, with new entrants aggressively using discounts and rebates in a stagnating market. Peck emphasized that this dynamic is not expanding the market, but instead increasing pressure on existing players. Cost Discipline and Strategic Investments: The company reduced operating expenses by 2% and SG&A by 4% year-over-year, reflecting deliberate cost actions. CFO Wetteny Joseph noted, \"We continue to demonstrate strong P&L discipline, protecting profitability through cost actions while staying focused on the investment behind our highest-return opportunities.\" Leadership Changes: Zoetis promoted Abhay Nayak to EVP and President of U.S. Commercial Operations to drive performance in its largest market. Additionally, Jay Saccaro will become EVP, Chief Financial Officer, and Chief Operating Officer to improve decision-making and operational agility. Diagnostics and Livestock Resilience: The ", "date_published": "2026-08-10T03:25:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:b79dfef99e14f83e6e7485a496aba4a45ab4c2e909ab425d2433d0cf424e054a", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "title": "Zoetis Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand offset growth in livestock, diagnostics and international markets. Pet-care pressures led to a lowered outlook. Declining veterinary visits, selective pet-owner spending and increased competition hurt companion-animal and dermatology sales; Zoetis now expects full-year organic operational revenue to decline 3%", "date_published": "2026-08-09T18:03:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:6838f53c6f3f703b8b8ee76edcd7400972bcdfd42c3d9c793d8412bf345ca8bc", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1wX2VBTG5vQWloUEd1czg2cHRLRVAzU0RaT3RuWVMzdk14R3NGSVNMeDJpR0dNWk5iNkhDa1l0bENMc3k4UjdBcW5LcFNwRUhLaExKQXA2WUxUN3I5RThFeFVsMjJnRTc1?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1wX2VBTG5vQWloUEd1czg2cHRLRVAzU0RaT3RuWVMzdk14R3NGSVNMeDJpR0dNWk5iNkhDa1l0bENMc3k4UjdBcW5LcFNwRUhLaExKQXA2WUxUN3I5RThFeFVsMjJnRTc1?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: Zoetis Inc (ZTS) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: Zoetis Inc (ZTS) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-08T11:15:06+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "Z1TS34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "Z1TS34", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/13e03cb9-bf64-475f-819c-4fe85c253b3b/"}]}}, {"id": "source:9b3795786718ebb32a2aef2b75d405832146ac2323ce8538f23e1a1b063dac5b", "url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBuQTRxRmJvckdvekx6TDFWR3ltWVk0UU9fbVRBZjNaTk1YUm12QXhrdF9EWjRrTmM0UFJGUG9VMDVTSW1XU2JMeWh3b1lzNi1ucTJncXhMbnhTMU1qSnFIWGVGQnRRVlRUdFE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiakFVX3lxTFBuQTRxRmJvckdvekx6TDFWR3ltWVk0UU9fbVRBZjNaTk1YUm12QXhrdF9EWjRrTmM0UFJGUG9VMDVTSW1XU2JMeWh3b1lzNi1ucTJncXhMbnhTMU1qSnFIWGVGQnRRVlRUdFE?oc=5", "title": "Proje\u00e7\u00f5es de Resultados: Teva Pharmaceutical Industries Ltd (TEVA) \u2014 LPA e Crescimento de Receita", "content_text": "Proje\u00e7\u00f5es de Resultados: Teva Pharmaceutical Industries Ltd (TEVA) \u2014 LPA e Crescimento de Receita", "date_published": "2026-08-08T02:12:30+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "T1EV34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "T1EV34", "name": "Teva Pharmaceutical Industries Limited", "sentiment_url": "https://sharemaestro.com/sentiment/d4f4d3ba-8cd7-4caa-aaf6-8ef281fc55fc/"}]}}, {"id": "source:ff369ca583de2ecc9036af73be13e496ec03a7a31542b291bc751df66c62161c", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE40cW84anpTYlIwNUZXcGJ5LTh3bTFjdHFkUDdhOUxNc01Ta2FBSzVTak5KMkJpS0huejIzUUdqZ3JOQlFQWVlIWFRzNHk0MHVPTVNpWGRIRWxjSnNncmF0amxaWmM5dmZodlBJQ0RTaU5LZlhnekE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE40cW84anpTYlIwNUZXcGJ5LTh3bTFjdHFkUDdhOUxNc01Ta2FBSzVTak5KMkJpS0huejIzUUdqZ3JOQlFQWVlIWFRzNHk0MHVPTVNpWGRIRWxjSnNncmF0amxaWmM5dmZodlBJQ0RTaU5LZlhnekE?oc=5", "title": "Not\u00edcias das A\u00e7\u00f5es da United Therapeutics Corp (UTHR)", "content_text": "Not\u00edcias das A\u00e7\u00f5es da United Therapeutics Corp (UTHR)", "date_published": "2026-08-08T02:08:27+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:57940c0e73816c0ffb67e673e73a248dd78733a9fb254f7f4f034d3f6611143c", "url": "https://finance.yahoo.com/healthcare/articles/hypera-sa-hypmy-q2-2026-210446659.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hypera-sa-hypmy-q2-2026-210446659.html", "title": "Hypera SA (HYPMY) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic GLP-1 ...", "content_text": "This article first appeared on GuruFocus. Net Revenue: R$2.34 billion, up 8.5% year-over-year. Sell-out Growth: 7.6% growth, driven by skin care, central nervous system, and gut health categories. Gross Margin: 61.8%, an increase of 1.7 percentage points compared to Q2 2025. EBITDA: R$755 million, with a margin of 32.3%. Net Income: Grew 15%, driven by lower financial expenses. Operating Cash Flow: R$819 million, representing 108.5% of EBITDA. Free Cash Flow: R$638 million. Net Debt: R$5.9 billion, equivalent to 2.1 times EBITDA for the last 12 months. Marketing Expenses: R$411 million, up 13.", "date_published": "2026-08-07T21:04:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HYPE3"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HYPE3", "name": "Hypera S.A.", "sentiment_url": "https://sharemaestro.com/sentiment/a4cef1c1-11e0-4bba-95ee-456c5e60f0c9/"}]}}, {"id": "source:71b3f357b34fe62720605e242a88d83e80db1f84b99f4be3c7270a96cfcdfde6", "url": "https://finance.yahoo.com/healthcare/articles/dnli-q2-loss-narrows-avlayah-183100129.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dnli-q2-loss-narrows-avlayah-183100129.html", "title": "DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum", "content_text": "Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major regulatory win with the FDA approval of its lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome (MPS II). The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. It is also the first approved therapy in a new class of biologics designed to cross the blood-brain barrier by targeting the transferrin receptor. The continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study. The company recorded net product revenues of $3.6 million in the second quarter, driven by the initial commercial sales of Avlayah in the United States following its FDA approval in March 2026. The reported number surpassed the Zacks Consensus Estimate of $1 million. DNLI did not record any revenues in the year-ago quarter. The stock is trading up in response to the quarterly results. Shares of DNLI have gained 49.8% year to date compared with the industry's 3.9% growth.Zacks Investment Research Image Source: Zacks Investment Research Highlights of DNLI's Q2 Results Research and development expenses decreased 11% to $97 million due to lower costs related to small molecule programs as well as lower clinical expenses for tividenofusp alfa. General and administrative expenses rose 14% to $36.3 million, primarily driven by higher personnel-related costs due to increased headcount to support the commercial launch of Avlayah. Intangible asset amortization was $0.7 million for the quarter, reflecting amortization of the developed technology intangible asset recognized upon FDA approval of Avlayah. In June 2026, Denali entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (\"PRV\"), awarded following the FDA approval of Avlayah, for gross proceeds of $195 million. Denali received the funds in July 2026. Cash, cash equivalents and marketable securities totaled approximately $940.0 million as of June 30, 2026. Following the receipt of $195.0 million in gross proceeds from the sale of a PRV in July 2026, the company's pro forma cash, cash equivalents and marketable securities exceeded $1.1 billion. Encouraging Uptake of DNLI's Avlayah Story Continues The U.S. launch of Avlayah gained strong traction during its first full quarter of commercialization, driven by favorable uptake among patients, caregivers and physicians, encouraging early treatment experiences and the rapid expansion of payer coverage. Initial demand for Avlayah has exceeded Denali's internal expectations, with early patient interest in initiating treatment tracking ahead of projections. Denali projects third-quarter 2026 Avlayah net product revenues of $10.0 million to $12.0 million. The ongoing global phase II/III COMPASS study is designed to generate confirmatory data, support the potential expansion of the U.S. label to include adult patients and enable future regulatory submissions worldwide. Denali Therapeutics Inc. Price, Consensus and EPS Surprise Denali Therapeutics Inc. price-consensus-eps-surprise-chart | Denali Therapeutics Inc. Quote DNLI's Key Pipeline Updates Denali is evaluating zafinofusp alfa (DNL126) for the treatment of Sanfilippo syndrome type A (MPS IIIA). It is an investigational intravenously administered ETV-enabled SGSH replacement therapy being developed to target the neurological and systemic manifestations of the disease by delivering the enzyme to both the brain and body. Preliminary results from the ongoing phase I/II study showed that zafinofusp alfa significantly reduced cerebrospinal fluid (CSF) and urine heparan sulfate (HS) levels, including normalization of", "date_published": "2026-08-07T18:31:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "TAKP34"], "_sharemaestro": {"country": "Brazil", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "TAKP34", "name": "Takeda Pharmaceutical Company Limited", "sentiment_url": "https://sharemaestro.com/sentiment/8cd97599-ad6b-4ba9-9cdd-c5a3b9e0ab13/"}]}}, {"id": "source:cd56984ecdc7cb747c43b7b98c387dab7f166d41979ec1e3dd1c6284d1118d87", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE9RYTZjRDQtQl9JaEdsaEI4Sm8ya3B5ZDhnVXpjeFloX0p2ZFVzaDFwNzR5UjlHcDhOUkNlMFFiU3E5ek8tZDR1UWxfamk3WjIzU1BMS3JKT2xFSk9zNDZYNG5Bc2ticGZCNjJZeWJhN3FVZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMickFVX3lxTE9RYTZjRDQtQl9JaEdsaEI4Sm8ya3B5ZDhnVXpjeFloX0p2ZFVzaDFwNzR5UjlHcDhOUkNlMFFiU3E5ek8tZDR1UWxfamk3WjIzU1BMS3JKT2xFSk9zNDZYNG5Bc2ticGZCNjJZeWJhN3FVZw?oc=5", "title": "United Therapeutics: EPS sobe 13% no 2\u00ba trimestre fiscal de 2026", "content_text": "United Therapeutics: EPS sobe 13% no 2\u00ba trimestre fiscal de 2026", "date_published": "2026-08-05T10:48:42+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:37654084a5a50eb3d793240ad041b38d6cf6a92c5281b6da4566e5029a242dde", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNamxTclBnSkFpeTRLRmc4N0JQc3FCM201N3JvNGhQWm5YMG0wSm9EZ2V1d1dGT0ZnQktxc01FVll3QXN0Nmx1UzU0Y1o4MHZRemZuZEU0OWU0TW1kRWcxU2staVY0X2lJRXdwbFl2bE4yakp1ZGcwYjZLV2FuR0pEZGVYdzZZLTNCT3NIQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNamxTclBnSkFpeTRLRmc4N0JQc3FCM201N3JvNGhQWm5YMG0wSm9EZ2V1d1dGT0ZnQktxc01FVll3QXN0Nmx1UzU0Y1o4MHZRemZuZEU0OWU0TW1kRWcxU2staVY0X2lJRXdwbFl2bE4yakp1ZGcwYjZLV2FuR0pEZGVYdzZZLTNCT3NIQQ?oc=5", "title": "As a\u00e7\u00f5es da United Therapeutics caem ap\u00f3s receita abaixo do esperado, apesar dos resultados superarem as expectativas", "content_text": "As a\u00e7\u00f5es da United Therapeutics caem ap\u00f3s receita abaixo do esperado, apesar dos resultados superarem as expectativas", "date_published": "2026-02-25T08:00:00+00:00", "authors": [{"name": "ADVFN"}], "tags": ["Market update", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}, {"id": "source:b08ab7933cf615724ac9dddc6fd7a5030a0324fcdd8ef908abd858e833200260", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE9mYTFPM2YtejdDMXNTeHplWDJXU2NHUzVKLTBNQzUtb3F4OXgxRl90TEdCU19scm5JQW9nMV8xUHpsVkxaMWNuU2QzVXhLVWRVR3c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE9mYTFPM2YtejdDMXNTeHplWDJXU2NHUzVKLTBNQzUtb3F4OXgxRl90TEdCU19scm5JQW9nMV8xUHpsVkxaMWNuU2QzVXhLVWRVR3c?oc=5", "title": "Stock United Therapeutics - Stock UTHR - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "content_text": "Stock United Therapeutics - Stock UTHR - Resultados, Dividendos, Cota\u00e7\u00e3o e Indicadores", "date_published": "2021-04-15T04:57:10+00:00", "authors": [{"name": "Investidor10"}], "tags": ["Market update", "U2TH34"], "_sharemaestro": {"country": "Brazil", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "U2TH34", "name": "United Therapeutics Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/0bc627d9-8ec9-4db4-95f0-b4722598e807/"}]}}]}